Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ: HALO) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 42.2% year on year to $376.7 million. The company expects the full year’s revenue to be around $1.76 billion, close to analysts’ estimates. Its non-GAAP profit of $1.60 per share was 5.3% above analysts’ consensus estimates.

Is now the time to buy HALO? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Halozyme Therapeutics’ first quarter results for 2026 were met with a positive market response, underpinned by substantial royalty revenue growth and the expanding adoption of subcutaneous drug delivery through its ENHANZE technology. CEO Helen Torley credited the quarter’s momentum to broader use of key partner products such as DARZALEX, VYVGART Hytrulo, and PHESGO, with royalty streams up 43% year-over-year. The company also benefited from ramping contributions from recently launched therapies, highlighting ongoing operational execution and demand for ENHANZE-enabled products.

Looking ahead, Halozyme’s guidance is anchored by expectations for continued growth from its initial portfolio of ENHANZE products and a pipeline that includes 13 potential partner launches post-2029. Management’s strategy emphasizes ongoing investment in manufacturing capacity for Hypercon, further partner nominations, and a new share buyback program. CEO Helen Torley stated, “We are in the early stages of realizing the value from our enhanced business, and we are investing in Hypercon and Surf Bio to drive the next blockbuster royalty business,” signaling a focus on durability and expansion of the royalty-driven model.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to increased uptake of ENHANZE-enabled therapies, a robust pace of new partner agreements, and the early impact of acquisitions such as Hypercon and Surf Bio.

• ENHANZE product adoption: Uptake of ENHANZE-enabled drugs like DARZALEX, VYVGART Hytrulo, and PHESGO drove strong royalty revenue, supported by expanding clinical indications and new launches. These products allow drugs to be delivered subcutaneously (under the skin), reducing treatment time for patients and improving convenience.
• Recent partnership expansion: Halozyme signed three new collaboration and licensing agreements in early 2026, including with major pharmaceutical companies like GSK, Vertex, and Oruka. These deals expand the ENHANZE and Hypercon portfolios and provide upfront payments, milestones, and long-term royalty potential.
• Hypercon momentum: Following the Hypercon acquisition, the company is investing in manufacturing capacity to offer end-to-end services for partners, aiming to initiate Phase I clinical trials for Hypercon-enabled products in 2027. Hypercon technology enables higher-concentration formulations that can be administered in smaller volumes, facilitating at-home treatment.
• Royalty revenue backlog: Management highlighted that only 25% of projected royalties from the initial 10 ENHANZE products have been realized, with approximately 66% expected between 2026 and 2032, suggesting a significant multiyear revenue stream ahead.
• Share buyback and capital allocation: A new $1 billion share repurchase authorization and plans for further debt reduction reflect a commitment to shareholder returns, while continued evaluation of M&A opportunities in drug delivery remains a lower near-term priority.

Drivers of Future Performance

Halozyme’s forward guidance is driven by continued growth of core ENHANZE products, accelerated partner pipeline expansion, and investments in next-generation drug delivery platforms such as Hypercon.

• Core royalty growth: Management expects the original 10 ENHANZE products to remain the primary revenue source through 2028, with label expansions and new clinical indications broadening their patient base and sustaining double-digit growth in royalty streams.
• Pipeline launches and partnerships: Up to 13 new ENHANZE partner products are anticipated to launch after 2029, supplemented by ongoing partner nominations and recently signed collaborations. New Hypercon programs are on track for clinical entry by 2027, with the potential to accelerate royalty diversification in the 2030s.
• Investment and operational risks: While management projects EBITDA margin improvement and robust free cash flow, they also acknowledged ongoing R&D investments and the need to scale manufacturing for Hypercon. Delays in clinical trial starts or regulatory changes could impact the pace of new product launches and royalty ramp.

Catalysts in Upcoming Quarters

Looking ahead, our analysts will watch (1) the pace of new ENHANZE and Hypercon clinical program initiations, (2) the commercial uptake and market share expansion of recently launched subcutaneous therapies, and (3) progress in manufacturing scale-up for Hypercon. We will also track the impact of new collaboration agreements and potential label expansions on royalty revenue trajectory.

Halozyme Therapeutics currently trades at $69.15, up from $66.41 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).

Stocks That Trumped Tariffs

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.